Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCC Cyclacel Pharmaceuticals	$7.82 -3.1%	$7.95	$3.08 ▼ $597.60	$17.52M	0.08	725,245 shs	26,329 shs
EVAX Evaxion A/S	$3.05 +0.7%	$2.71	$1.20 ▼ $17.75	$4.27M	0.13	938,132 shs	14,624 shs
HOTH Hoth Therapeutics	$1.21	$1.28	$0.65 ▼ $3.80	$16.05M	0.66	3.86 million shs	162,561 shs
IXHL Incannex Healthcare	$0.62 -7.8%	$0.47	$0.08 ▼ $3.12	$18.19M	7.67	65.80 million shs	89.64 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCC Cyclacel Pharmaceuticals	+7.74%	+10.25%	-47.56%	-66.38%	-97.10%
EVAX Evaxion A/S	-2.57%	+2.71%	+3.41%	+31.74%	-81.47%
HOTH Hoth Therapeutics	-1.63%	-3.20%	-7.63%	+39.51%	+65.75%
IXHL Incannex Healthcare	-5.56%	+65.51%	-43.67%	+204.68%	-65.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCC Cyclacel Pharmaceuticals	1.1567 of 5 stars	0.0	4.0	2.7	2.5	0.0
EVAX Evaxion A/S	2.3448 of 5 stars	3.5	2.0	2.2	1.7	0.6
HOTH Hoth Therapeutics	2.8239 of 5 stars	3.5	5.0	2.5	0.0	0.6
IXHL Incannex Healthcare	0.2272 of 5 stars	0.0	2.0	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
EVAX Evaxion A/S	3.00	Buy	$10.00	227.87% Upside
HOTH Hoth Therapeutics	3.00	Buy	$4.00	230.58% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EVAX, CYCC, IXHL, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCC Cyclacel Pharmaceuticals	$40K	437.92	N/A	N/A	$1.62 per share	4.83
EVAX Evaxion A/S	$3.34M	1.28	N/A	N/A	$4.44 per share	0.69
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
IXHL Incannex Healthcare	$10K	1,818.77	N/A	N/A	$0.18 per share	3.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	11/10/2025 (Estimated)
EVAX Evaxion A/S	-$10.57M	-$1.32	N/A	N/A	N/A	-316.03%	-319.52%	-63.56%	10/30/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	11/11/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)

Latest EVAX, CYCC, IXHL, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVAX Evaxion A/S	-$0.50	-$0.76	-$0.26	-$0.76	N/A	$0.04 million
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.77
EVAX Evaxion A/S	1.73	3.42	3.42
HOTH Hoth Therapeutics	N/A	27.54	27.54
IXHL Incannex Healthcare	N/A	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYCC Cyclacel Pharmaceuticals	23.58%
EVAX Evaxion A/S	11.04%
HOTH Hoth Therapeutics	7.08%
IXHL Incannex Healthcare	0.43%

Insider Ownership

Company	Insider Ownership
CYCC Cyclacel Pharmaceuticals	51.20%
EVAX Evaxion A/S	41.64%
HOTH Hoth Therapeutics	6.92%
IXHL Incannex Healthcare	15.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCC Cyclacel Pharmaceuticals	14	2.24 million	1.09 million	Optionable
EVAX Evaxion A/S	60	1.40 million	819,000	No Data
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable

EVAX, CYCC, IXHL, and HOTH Headlines

Recent News About These Companies

Cannabis Stocks To Keep An Eye On - August 25th

August 28 at 4:25 AM | americanbankingnews.com

Cannabis Stocks To Watch Today - August 26th

August 28 at 2:00 AM | americanbankingnews.com

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

August 26 at 8:00 AM | globenewswire.com

Top Cannabis Stocks To Keep An Eye On - August 23rd

August 26 at 2:13 AM | americanbankingnews.com

Promising Cannabis Stocks To Follow Now - August 24th

August 26 at 2:27 AM | americanbankingnews.com

Best Cannabis Stocks To Consider - August 22nd

August 25 at 5:01 AM | americanbankingnews.com

Top Cannabis Stocks To Follow Now - August 21st

August 24, 2025 | americanbankingnews.com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

August 22, 2025 | msn.com

Incannex Healthcare Inc. Launches $20 Million Share Repurchase Program to Enhance Shareholder Value

August 22, 2025 | quiverquant.comQ

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

August 22, 2025 | globenewswire.com

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

August 19, 2025 | newsfilecorp.comN

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

August 17, 2025 | msn.com

Incannex Healthcare: Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 9, 2025 | finanznachrichten.de

Incannex Shares Surge Following Promising Sleep Apnea Trial Data

August 8, 2025 | msn.com

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 8, 2025 | globenewswire.com

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

July 31, 2025 | globenewswire.com

Incannex reports results from RePOSA Phase 2 trial of IHL-42X

July 30, 2025 | msn.com

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

July 30, 2025 | globenewswire.com

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

July 25, 2025 | globenewswire.com

Incannex Expands ATM Offering by $100 Million

July 24, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX, CYCC, IXHL, and HOTH Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:CYCC

$7.82 -0.25 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$7.96 +0.14 (+1.79%)

As of 05:31 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Evaxion A/S NASDAQ:EVAX

$3.05 +0.02 (+0.66%)

Closing price 03:59 PM Eastern

Extended Trading

$3.04 -0.01 (-0.49%)

As of 05:37 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Hoth Therapeutics NASDAQ:HOTH

$1.21 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.02 (+1.65%)

As of 05:41 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Incannex Healthcare NASDAQ:IXHL

$0.62 -0.05 (-7.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 -0.01 (-1.94%)

As of 05:45 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time